Search

Your search keyword '"Frederique, Renè"' showing total 2 results
Start Over Author "Frederique, Renè"
2 results on '"Frederique, Renè"'

1. Skeletal-Muscle Metabolic Reprogramming in ALS-SOD1G93A Mice Predates Disease Onset and Is A Promising Therapeutic Target

Author

Silvia Scaricamazza, Illari Salvatori, Giacomo Giacovazzo, Jean Philippe Loeffler, Frederique Renè, Marco Rosina, Cyril Quessada, Daisy Proietti, Constantin Heil, Simona Rossi, Stefania Battistini, Fabio Giannini, Nila Volpi, Frederik J. Steyn, Shyuan T. Ngo, Elisabetta Ferraro, Luca Madaro, Roberto Coccurello, Cristiana Valle, and Alberto Ferri

Subjects
Drugs, Molecular Neuroscience, Cellular Neuroscience, Science
Abstract

Summary: Patients with ALS show, in addition to the loss of motor neurons in the spinal cord, brainstem, and cerebral cortex, an abnormal depletion of energy stores alongside hypermetabolism. In this study, we show that bioenergetic defects and muscle remodeling occur in skeletal muscle of the SOD1G93A mouse model of ALS mice prior to disease onset and before the activation of muscle denervation markers, respectively. These changes in muscle physiology were followed by an increase in energy expenditure unrelated to physical activity. Finally, chronic treatment of SOD1G93A mice with Ranolazine, an FDA-approved inhibitor of fatty acid β-oxidation, led to a decrease in energy expenditure in symptomatic SOD1G93A mice, and this occurred in parallel with a robust, albeit temporary, recovery of the pathological phenotype.

Published
2020
Full Text
View/download PDF

2. Repurposing of Trimetazidine for amyotrophic lateral sclerosis: A study in SOD1

Author

Silvia, Scaricamazza, Illari, Salvatori, Susanna, Amadio, Valentina, Nesci, Alessio, Torcinaro, Giacomo, Giacovazzo, Aniello, Primiano, Michela, Gloriani, Niccolò, Candelise, Luisa, Pieroni, Jean-Philippe, Loeffler, Frederique, Renè, Cyril, Quessada, Tesfaye W, Tefera, Hao, Wang, Frederik J, Steyn, Shyuan T, Ngo, Gabriella, Dobrowolny, Elisa, Lepore, Andrea, Urbani, Antonio, Musarò, Cinzia, Volonté, Elisabetta, Ferraro, Roberto, Coccurello, Cristiana, Valle, and Alberto, Ferri

Subjects
Male, Disease Models, Animal, Mice, Superoxide Dismutase-1, Superoxide Dismutase, Amyotrophic Lateral Sclerosis, Drug Repositioning, Trimetazidine, Animals, Female, Mice, Transgenic, Neurodegenerative Diseases
Abstract

Amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the degeneration of upper and lower motor neurons, progressive wasting and paralysis of voluntary muscles and is currently incurable. Although considered to be a pure motor neuron disease, increasing evidence indicates that the sole protection of motor neurons by a single targeted drug is not sufficient to improve the pathological phenotype. We therefore evaluated the therapeutic potential of the multi-target drug used to treatment of coronary artery disease, trimetazidine, in SOD1As a metabolic modulator, trimetazidine improves glucose metabolism. Furthermore, trimetazidine enhances mitochondrial metabolism and promotes nerve regeneration, exerting an anti-inflammatory and antioxidant effect. We orally treated SOD1Trimetazidine administration delays motor function decline, improves muscle performance and metabolism, and significantly extends overall survival of SOD1In SOD1

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results